Sunzen Biotech Berhad Yönetim

Yönetim kriter kontrolleri 3/4

Sunzen Biotech Berhad CEO'su Yek Teo, Jun2020 tarihinde atandı, in görev süresi 4.42 yıldır. in toplam yıllık tazminatı MYR 320.94K olup, şirket hissesi ve opsiyonları dahil olmak üzere 84.1% maaş ve 15.9% ikramiyelerden oluşmaktadır. şirketin hisselerinin 15.19% ine doğrudan sahiptir ve bu hisseler MYR 37.33M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3 yıl ve 4.3 yıldır.

Anahtar bilgiler

Yek Teo

İcra Kurulu Başkanı

RM 320.9k

Toplam tazminat

CEO maaş yüzdesi	84.1%
CEO görev süresi	4.4yrs
CEO sahipliği	15.2%
Yönetim ortalama görev süresi	3yrs
Yönetim Kurulu ortalama görev süresi	4.3yrs

Son yönetim güncellemeleri

Recent updates

Sunzen Biotech Berhad's (KLSE:SUNZEN) Promising Earnings May Rest On Soft Foundations

Nov 07

Sunzen Biotech Berhad's (KLSE:SUNZEN) Shareholders Might Be Looking For Exit

Oct 15

Sunzen Biotech Berhad's (KLSE:SUNZEN) Returns On Capital Are Heading Higher

Aug 06

If EPS Growth Is Important To You, Sunzen Biotech Berhad (KLSE:SUNZEN) Presents An Opportunity

May 25

Optimistic Investors Push Sunzen Biotech Berhad (KLSE:SUNZEN) Shares Up 27% But Growth Is Lacking

May 24

Sunzen Biotech Berhad (KLSE:SUNZEN) Is Doing The Right Things To Multiply Its Share Price

Apr 22

Sunzen Biotech Berhad (KLSE:SUNZEN) Shareholders Will Want The ROCE Trajectory To Continue

Jan 19

What Sunzen Biotech Berhad's (KLSE:SUNZEN) 27% Share Price Gain Is Not Telling You

Nov 16

Health Check: How Prudently Does Sunzen Biotech Berhad (KLSE:SUNZEN) Use Debt?

Mar 26

Is Sunzen Biotech Berhad (KLSE:SUNZEN) Weighed On By Its Debt Load?

Dec 10

CEO Tazminat Analizi

Yek Teo'un ücretlendirmesi Sunzen Biotech Berhad'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	RM 321k	RM 270k	RM 6m
Dec 31 2023	n/a	n/a	RM 7m
Sep 30 2023	n/a	n/a	RM 5m
Jun 30 2023	n/a	n/a	RM 4m
Mar 31 2023	n/a	n/a	RM 4m
Dec 31 2022	RM 214k	RM 175k	RM 4m
Sep 30 2022	n/a	n/a	RM 3m
Jun 30 2022	n/a	n/a	RM 2m
Mar 31 2022	n/a	n/a	RM 2m
Dec 31 2021	RM 148k	RM 120k	RM 680k
Sep 30 2021	n/a	n/a	-RM 9m
Jun 30 2021	n/a	n/a	-RM 9m
Mar 31 2021	n/a	n/a	-RM 11m
Dec 31 2020	RM 74k	RM 65k	-RM 13m

Tazminat ve Piyasa: Yek 'nin toplam tazminatı ($USD 71.83K ), MY pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 108.01K ).

Tazminat ve Kazançlar: Yek 'in maaşı son bir yılda %20'den fazla arttı.

CEO

Yek Teo (40 yo)

4.4yrs

Görev süresi

RM 320,938

Tazminat

Mr. Yek Ming Teo serves as Executive Director at Sunzen Biotech Berhad since June 16, 2020 and served as its Group Managing Director cum Group Chief Executive Officer since June 16, 2020 until February 25,...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Chee Ching	Executive Chairman	4.3yrs	RM 114.52k	0.53% MYR 1.3m
Yek Teo	Group MD & Executive Director	4.4yrs	RM 320.94k	15.19% MYR 37.3m
Tong Phang	Chief Financial Officer	no data	Veri yok	Veri yok
Wee Lim	Sales & Marketing Director	no data	Veri yok	Veri yok
Mee Teo	Company Secretary	10yrs	Veri yok	Veri yok
Weng Cheng	Joint Company Secretary	less than a year	Veri yok	Veri yok

3.0yrs

Ortalama Görev Süresi

47.5yo

Ortalama Yaş

Deneyimli Yönetim: SUNZEN 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Chee Ching	Executive Chairman	4.3yrs	RM 114.52k	0.53% MYR 1.3m
Yek Teo	Group MD & Executive Director	4.4yrs	RM 320.94k	15.19% MYR 37.3m
Yew Lee	Non Independent Non-Executive Director	4.3yrs	RM 96.80k	Veri yok
Kien Khoo	Independent Non-Executive Director	10.3yrs	RM 43.80k	Veri yok
Long Poo	Independent & Non-Executive Director	1.7yrs	RM 39.06k	0.011% MYR 26.2k
Aida Binti Abdullah	Senior Independent & Non Executive Director	less than a year	RM 35.40k	Veri yok

4.3yrs

Ortalama Görev Süresi

49yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: SUNZEN 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.3 yıldır).

Sunzen Biotech Berhad Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Sunzen Biotech Berhad, Annual General Meeting, Dec 19, 2024

Sunzen Biotech Berhad, Annual General Meeting, Dec 19, 2024

Sunzen Biotech Berhad Announces Appointment of Aida Lim Binti Abdullah as Independent and Non Executive Member of Nomination Committee

Sunzen Biotech Berhad Announces Resignation of Zeenath Begum Binti Mohamed Mastan as Joint Company Secretary

Sunzen Biotech Berhad Announces Appointment of Lee Yew Weng as Non Independent and Non Executive Member of Remuneration Committee

Sunzen Biotech Berhad Appoints Lee Yew Weng as Non Independent and Non Executive Member of Nomination Committee

Recent updates

Sunzen Biotech Berhad's (KLSE:SUNZEN) Promising Earnings May Rest On Soft Foundations

Sunzen Biotech Berhad, Annual General Meeting, Dec 19, 2024

Sunzen Biotech Berhad, Annual General Meeting, Dec 19, 2024

Sunzen Biotech Berhad's (KLSE:SUNZEN) Shareholders Might Be Looking For Exit

New major risk - Shareholder dilution

Sunzen Biotech Berhad (KLSE:SUNZEN) acquired additional 30% stake in Ecolite Biotech Manufacturing Sdn Bhd from group of sellers for MYR 15 million.

Sunzen Biotech Berhad's (KLSE:SUNZEN) Returns On Capital Are Heading Higher

Now 22% undervalued

If EPS Growth Is Important To You, Sunzen Biotech Berhad (KLSE:SUNZEN) Presents An Opportunity

Optimistic Investors Push Sunzen Biotech Berhad (KLSE:SUNZEN) Shares Up 27% But Growth Is Lacking

Sunzen Biotech Berhad (KLSE:SUNZEN) Is Doing The Right Things To Multiply Its Share Price

Sunzen Biotech Berhad (KLSE:SUNZEN) Shareholders Will Want The ROCE Trajectory To Continue

Sunzen Biotech Berhad Announces Appointment of Aida Lim Binti Abdullah as Independent and Non Executive Member of Nomination Committee

Third quarter 2023 earnings released: EPS: RM0.002 (vs RM0.001 in 3Q 2022)

Sunzen Biotech Berhad Announces Resignation of Zeenath Begum Binti Mohamed Mastan as Joint Company Secretary

What Sunzen Biotech Berhad's (KLSE:SUNZEN) 27% Share Price Gain Is Not Telling You

Sunzen Biotech Berhad Announces Appointment of Lee Yew Weng as Non Independent and Non Executive Member of Remuneration Committee

Sunzen Biotech Berhad Appoints Lee Yew Weng as Non Independent and Non Executive Member of Nomination Committee

Second quarter 2023 earnings released: EPS: RM0.001 (vs RM0.001 in 2Q 2022)

Sunzen Biotech Berhad Announces the Resignation of Dr. Fong Chan Seng as Independent and Non Executive Director, Member of Remuneration Committee, Chairman of Nomination Committee

First quarter 2023 earnings released: EPS: RM0.002 (vs RM0.001 in 1Q 2022)

Sunzen Biotech Berhad Announces Redesignation of Ching Chee Pun as Executive Chairman

Full year 2022 earnings released: EPS: RM0.005 (vs RM0.001 in FY 2021)

Third quarter 2022 earnings released: EPS: RM0.001 (vs RM0 in 3Q 2021)

Second quarter 2022 earnings released: EPS: RM0.001 (vs RM0 in 2Q 2021)

First quarter 2022 earnings released: EPS: RM0.001 (vs RM0 in 1Q 2021)

Sunzen Biotech Berhad Announces Resignation of Lim Lee Kuan as Company Secretary

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Sunzen Biotech Berhad Announces the Re-Designation of Teo Yek Ming from Group Chief Executive Officer to Group Managing Director

Sunzen Biotech Berhad (KLSE:SUNZEN) completed the acquisition of Finsource Solution Sdn Bhd from Teo Yek Ming, Ching Chee Pun, Lee Ching Yong and Low Chee Yeap.

Health Check: How Prudently Does Sunzen Biotech Berhad (KLSE:SUNZEN) Use Debt?

Full year 2020 earnings released: RM0.025 loss per share (vs RM0.034 loss in FY 2019)

New 90-day high: RM0.22

Sunzen Biotech Berhad (KLSE:SUNZEN) entered into a conditional share sale agreement to acquire Finsource Solution Sdn Bhd from Teo Yek Ming, Ching Chee Pun, Lee Ching Yong and Low Chee Yeap for MYR 12.4 million.

New 90-day high: RM0.20

Is Sunzen Biotech Berhad (KLSE:SUNZEN) Weighed On By Its Debt Load?

Third quarter 2020 earnings released: RM0.001 loss per share

Sunzen Biotech Berhad Announces Re-Designation of Ching Chee Pun from Non-Independent Director to Executive Director

First half earnings released

New 90-day high - RM0.21

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş